Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Coegin Pharma
Download the release

The Nomination Committee of Coegin Pharma has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on May 22, 2025.

The following individuals have been appointed as members of the Nomination Committee for the 2026 Annual General Meeting:

  • Johan Arver (Chair), representing Alveco Invest AB.
  • Martin Tisell, representing own shareholdings.
  • Rune Löderup, representing own shareholdings.
  • Eva Sjökvist Saers, in her capacity as Chair of the Board of Directors of Coegin Pharma AB.

The Nomination Committee is tasked with performing the duties assigned to it according to the Swedish Corporate Governance Code. The Committee is responsible for preparing proposals for the 2026 Annual General Meeting regarding the Chair of the Meeting, the Board of Directors, the Chair of the Board, the auditor, board and auditor fees, as well as any potential changes to the guidelines for the Nomination Committee.

The Annual General Meeting will be held on May 21, 2026 in Lund, Sweden. 

Shareholders who wish to submit proposals to the Nomination Committee are welcome to do so no later than January 15, 2026. Proposals should be sent via email to info@coeginpharma.com.

The Nomination Committee's proposals will be presented in the notice of the Annual General Meeting, as well as on the company's website, www.coeginpharma.com. 

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com

 

Attached files

251127-Press-release.pdf
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.